UroToday - Combination Chemotherapy with Weekly Docetaxel and Estramustine for Hormone Refractory Prostate Cancer in Japanese Patients - Abstract

[Guest guest]

http://www.urotoday.com/browse_categories/prostate_cancer/combination_chemotherapy_with_weekly_docetaxel_and_estramustine_for_hormone_refractory_prostate_cancer_in_japanese_patients__abstract.html

Wednesday, 30 January 2008

Division

of Urology, Department of Organ Therapeutics, Kobe University Graduate School

of Medicine, 7-5-1, Kusunoki-cho, Chu-ku, Kobe,

Japan

The aim

is to evaluate the efficacy and toxicity of weekly docetaxel and estramustine for

Japanese men with hormone refractory prostate cancer who were treated at a

single institution. Twenty eligible patients had histologically proven

adenocarcinoma of the prostate with metastases that were progressing despite

complete androgen blockade and antiandrogen withdrawal. All of the patients

received docetaxel 30 mg/m(2) weekly (days 1, 8, 15, 22, 29, and 36). After a

two week break, the treatment schedule was repeated. Patients

were scheduled to receive daily oral estramustine 560 mg/day throughout the

protocol. In the serum prostate specific antigen (PSA) response, three (15%)

patients achieved a complete response, and 8 (40%) acheived a partial response.

Overall survival and time to progression were 13.4 months and 6.4 months,

respectively, however sixty-seven percent of the patients had to discontinue

treatment because of toxicity. The high toxicity of this protocol suggests that

the regimen and/or the timing should be altered for Japanese patients.

Written

by

Takenaka A, Yamada Y, Kurahashi T, Soga H, Miyake H, Fujisawa M.

Reference

Int

J Urol. 2008 Jan;15(1):106-9

doi:10.1111/j.1442-2042.2007.01929.x

PubMed

Abstract

PMID:18184188